

Monterrey, Mexico. February 12, 2020 – Alpek, S.A.B. de C.V. (BMV: ALPEK)

Alpek 4Q19 Reported EBITDA of U.S. \$356 million (U.S. \$172 million Comp. EBITDA)

Selected Financial Information

(U.S. \$ Millions)

			(%) 4Q19 vs.		2019	2018	Ch.%	
	4Q19	3Q19	4Q18	3Q19				4Q18
Total Volume (ktons)	1,059	1,118	1,061	(5)	-	4,384	4,402	-
Polyester	851	895	851	(5)	-	3,490	3,490	-
Plastics & Chemicals	208	223	210	(7)	(1)	895	912	(2)
Consolidated Revenues	1,407	1,523	1,758	(8)	(20)	6,216	6,991	(11)
Polyester	1,075	1,162	1,295	(7)	(17)	4,718	5,174	(9)
Plastics & Chemicals	311	345	400	(10)	(22)	1,407	1,713	(18)
Consolidated EBITDA	356	194	369	83	(4)	850	1,063	(20)
Polyester	122	129	316	(6)	(61)	428	788	(46)
Plastics & Chemicals	42	60	52	(30)	(18)	218	276	(21)
Cogeneration Plants' Sale	188	-	-	100	100	188	-	100
Profit Attributable to Controlling Interest	209	50	393	316	(47)	342	697	(51)
CAPEX and Acquisitions	115	49	262	(133)	(56)	270	826	(67)
Net Debt	1,330	2,036	1,832	(35)	(27)			
Net Debt / EBITDA ⁽¹⁾	1.6	2.4	1.7					
Interest Coverage ⁽¹⁾	7.2	7.8	9.9					

(1) Times: Last 12 months

Operating & Financial Highlights (4Q19)

Alpek	<ul style="list-style-type: none"> 4Q19 Comparable EBITDA of U.S. \$172 million (-19% qoq and -5% yoy) Finalized cogeneration plants' sale for U.S. \$801 million, generating an extraordinary gain of U.S. \$188 million in 4Q19 Agreement to acquire 350KTA PET facility in Wilton, UK improving PTA/PET capacity balance Net Debt reduced by U.S. \$706 million improving leverage to 1.6x Net Debt / EBITDA
Polyester	<ul style="list-style-type: none"> 4Q19 Comparable Polyester EBITDA of U.S. \$123 million (-15% qoq and flat yoy), including a U.S. \$2 million non-cash inventory loss and U.S.\$1 million gain from other extraordinary items U.S. Px prices fell 2% in 4Q, generating low inventory loss & raw material carry-forward effect 2019 Reference polyester margins of U.S. \$306 per ton, above guidance but declining in 4Q
Plastics & Chemicals (P&C)	<ul style="list-style-type: none"> 4Q19 Comparable P&C EBITDA of U.S. \$46 million (-29% qoq and -19% yoy) P&C EBITDA affected by lower Polypropylene ("PP") volume vs. 3Q19 and margins vs. 4Q18

This release contains forward-looking information based on numerous variables and assumptions that are inherently uncertain. They involve judgments with respect to, among other things, future economic, competitive and financial market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Accordingly, results could vary from those set forth in this release. The report presents unaudited financial information based on International Financial Reporting Standards (IFRS). Figures are stated in nominal Mexican pesos (\$) and in current U.S. Dollars (U.S. \$), as indicated. Where applicable, peso amounts were translated into U.S. Dollars using the average exchange rate of the months during which operations were recorded. Financial ratios are calculated in U.S. Dollars. Due to the rounding up of figures, small differences may occur when calculating percent changes from one period to the other.

Message from the CEO

In 2019, Alpek recorded one of its best years ever, posting its second highest EBITDA in history, despite a declining raw material price environment throughout the year. 4Q19 Consolidated EBITDA was U.S. \$356 million, including a U.S. \$188 million extraordinary gain as the sale of its two power cogeneration assets was concluded, and 2019 Consolidated EBITDA totaled U.S. \$850 million. Excluding inventory losses and other non-recurring items, Alpek's 4Q19 and 2019 Comparable EBITDA was U.S. \$172 million and U.S. \$722 million respectively.

Average spot Brent crude oil and U.S. reference paraxylene ("Px") prices remained stable during the fourth quarter, increasing by 1% and decreasing by 2%, respectively. In Plastics and Chemicals ("P&C"), propylene ("PGP") contract prices decreased 15% throughout the quarter. This relative price stability, when compared to the rest of 2019, resulted in a non-cash inventory loss of only U.S. \$6 million during the fourth quarter and a net, non-cash inventory loss of U.S. \$68 million for the full year.

Polyester segment EBITDA was U.S. \$122 million in 4Q19, including a U.S. \$2 million non-cash inventory loss and a U.S. \$1 million net gain from other non-recurring items. Adjusting for these effects, 4Q19 Comparable Polyester EBITDA was U.S. \$123 million, down 15% but flat when compared to 3Q19 and 4Q18, respectively. The decrease versus 3Q19 was primarily attributed to lower volume linked to typical seasonal effects.

Plastics & Chemicals segment EBITDA was U.S. \$42 million in 4Q19. Adjusting for non-cash inventory losses of U.S. \$4 million, Comparable P&C EBITDA was U.S. \$46 million, down 29% quarter on quarter and 19% year on year. The decrease versus 3Q19 mainly derives from a lower polypropylene sales volume, while the difference versus 4Q18 is largely due to higher polypropylene margins at the time.

The stable paraxylene prices observed during 4Q19 also generated a negative raw material carry-forward effect ("RMCF") of only U.S. \$2 million during the quarter, and a cumulative negative RMCF effect of U.S. \$67 million for the full year. Excluding this effect, Comparable EBITDA would have reached U.S. \$173 million and U.S. \$789 million for 4Q19 and 2019, respectively.

On the investment front, Alpek continued advancing strategically on its growth plan. Capex totaled U.S. \$115 million and U.S. \$270 million, for the fourth quarter and year, respectively. During the year, funds were invested into the completion of construction of the Altamira cogeneration power plant, and the acquisition of Perpetual's rPET facility, among others.

During 4Q19 Alpek completed the sale of its two cogeneration power plants located in Cosoleacaque and Altamira, Mexico, for U.S. \$801 million. Net proceeds from the sale were used to pay down debt shortly thereafter, as well as to decree a one-time dividend of U.S. \$143 million. It is important to note that Alpek sites will continue to enjoy the benefits of being energy and steam offtakers of these plants.

Likewise, over the quarter, Alpek reached an agreement with Lotte Chemical Corporation to acquire a 350,000 ton PET facility located in Wilton, United Kingdom, and met all regulatory requirements to officially take over operations as of 2020. This marks the company's first acquisition outside the Americas. It also allows Alpek to better balance its PTA and PET productive capacities, as the site's PTA requirements will be internally supplied by Alpek.

Alpek's financial position improved considerably throughout the year. As of year-end, Net Debt totaled U.S. \$1.330 billion and the leverage ratio (Net Debt to LTM EBITDA) was 1.6 times, down from 2.4 times and 1.7 times at the close of 3Q19 and 2018, respectively. The proceeds from the sale of the cogeneration power plants, as well as profits from operations, allowed net debt to decrease by U.S. \$706 million in 4Q19.

2019 Comparable EBITDA figures reflect better-than-expected margins across both segments, volume on par to 2018 record levels, the successful completion of the power cogeneration assets' sale, and a lessening inventory adjustment & raw material carry-forward effect towards the end of the year.

Our outlook for 2020 is positive as Alpek's long-term growth plan, focused on strengthening our core business, strategic acquisitions, and fostering a circular economy for our products, continues yielding results. We expect an increase in sales volume, improvements to operating costs, as well as an advantaged financial position as of the start of 2020. We are also considering a favorable feedstock price environment with stable Brent oil prices and a continuation of low prices for paraxylene and propylene. We do, however, expect lower margins in Polyester, as global trade conditions have impacted supply/demand balance, and in P&C, as new polypropylene capacity will be added in North America in the second half of the year. 2020 Guidance will be disclosed tomorrow, prior to our 4Q19 Earnings Conference Call.

Results by Business Segment

Polyester

(Purified Terephthalic Acid (PTA), Polyethylene Terephthalate (PET), rPET, Polyester fibers – 76% of Alpek's Net Sales)

Fourth quarter 2019 Polyester revenue was down 7% quarter-on-quarter as a result of lower volume and average prices. 4Q19 revenue was down 17% year-on-year mainly due to lower feedstock prices versus 4Q18. Average 4Q19 polyester prices decreased 3% and 17% when compared to 3Q19 and 4Q18, respectively.

Polyester volume was 851 Ktons in 4Q19, down 5% and flat when compared to 3Q19 and 4Q18, respectively. The variation versus 3Q19 was mainly due to normal PET sales seasonality. For the full year, Polyester volume was flat vs 2018 record levels.

4Q19 segment EBITDA was U.S. \$122 million, including a U.S. \$2 million non-cash inventory loss and a U.S. \$1 million net gain from other non-recurring items. Adjusting for these items, 4Q19 Comparable Polyester EBITDA was U.S. \$123 million, down 15% and flat when compared to 3Q19 and 4Q18, respectively. 2019 Comparable Polyester EBITDA was U.S. \$474 million, down 10% when compared to 2018, as a result of lower margins versus extraordinarily high levels last year. As expected, the raw material carry-forward effect in the quarter was negligible, however the impact for the full year accounted for U.S. \$67 million.

Plastics & Chemicals (P&C)

(Polypropylene (PP), Expandable Polystyrene (EPS), Caprolactam (CPL), Other products – 23% of Alpek's Net Sales)

4Q19 P&C revenue was down 10% and 22% quarter-on-quarter and year-on-year, respectively, mainly as a result of lower average prices. 4Q19 average P&C prices were down 3% and 21% when compared to those of 3Q19 and 4Q18, respectively, reflecting lower prices for feedstocks such as propylene and styrene.

Quarterly P&C volume decreased 7% and 1%, when compared to 3Q19 and 4Q18, respectively. The reduction versus 3Q19 mainly derives from lower polypropylene sales, typical of demand seasonality. For the full year, P&C volume was 2% lower than 2018, as the year-on-year increase in PP volume was offset by lower caprolactam sales and commercialization of industrial chemicals.

Segment EBITDA was U.S. \$42 million in 4Q19, including a U.S. \$4 million non-cash inventory loss. Adjusting for the inventory loss, 4Q19 Comparable P&C EBITDA was U.S. \$46 million, down 29% and 19% quarter-on-quarter and year-on-year, respectively. The reduction versus last quarter mainly stems from lower polypropylene sales volume, while the difference versus 4Q18 was due to higher polypropylene margins at the time.

Consolidated Financial Results

Net Sales: Net Sales for the fourth quarter totaled U.S. \$1.407 billion, 8% and 20% lower when compared to 3Q19 and 4Q18, respectively. 4Q19 average consolidated prices were down 2% and 20% quarter-on-quarter and year-on-year, mainly driven by lower feedstock prices. Accumulated net sales as of December 31, 2019 totaled U.S. \$6.216 billion, 11% lower versus 2018.

EBITDA: 4Q19 Consolidated EBITDA was U.S. \$356 million, including an extraordinary gain of U.S. \$188 million from the sale of the two cogeneration power plants, a U.S. \$6 million non-cash inventory loss, and a U.S. \$1 million net gain from other non-recurring items. Adjusting for these items, Comparable Consolidated EBITDA was U.S. \$172 million, versus U.S. \$213 million and U.S. \$181 million in 3Q19 and 4Q18, respectively. As of December 31, 2019, accumulated Consolidated EBITDA was U.S. \$850 million and accumulated Comparable EBITDA totaled U.S. \$722 million. 2019 Consolidated EBITDA includes U.S. \$40 million from the operation of the cogeneration facilities before their sale.

Profit (Loss) Attributable to Controlling Interest: Profit Attributable to Controlling Interest for the fourth quarter of 2019 was U.S. \$209 million, compared to U.S. \$50 million in 3Q19 and U.S. \$393 million in 4Q18. 4Q19 Profit Attributable to Controlling Interest includes an extraordinary gain related to the sale of the cogeneration plants. Accumulated Profit Attributable to Controlling Interest as of December 31, 2019 was U.S. \$342 million, down 51% when compared to 2018.

Capital Expenditures and Acquisitions (Capex): 4Q19 Capex was U.S. \$115 million, compared to U.S. \$49 million and U.S. \$262 million in 3Q19 and 4Q18, respectively. Most of these funds were used to complete work at the Altamira cogeneration power plant, as well as minor asset replacements. Accumulated Capex as of December 31, 2019 totaled U.S. \$270 million, down 67% when compared to 2018.

Net Debt: Consolidated Net Debt as of December 31, 2019 was U.S. \$1.330 billion, down 35% and 27% quarter-on-quarter and year-on-year, respectively. Net Debt decreased by U.S. \$706 million during 4Q19 as proceeds from the cogeneration plants' sale were received. As of December 31, 2019, Gross Debt was U.S. \$1.716 billion and Cash totaled U.S. \$386 million. Financial ratios as of quarter-end were: Net Debt to EBITDA of 1.6 times and Interest Coverage of 7.2 times.

Appendix A - Tables

TABLE 1 | VOLUME (KTONS)

	4Q19	3Q19	4Q18	(% 4Q19 vs.)		2019	2018	Ch.%
				3Q19	4Q18			
Total Volume	1,059	1,118	1,061	(5)	-	4,384	4,402	-
Polyester	851	895	851	(5)	-	3,490	3,490	-
Plastics and Chemicals	208	223	210	(7)	(1)	895	912	(2)

TABLE 2 | PRICE CHANGES (%)

	(% 4Q19 vs.)		2019 vs. 2018
	3Q19	4Q18	
Polyester			
Avg. Ps. Prices	(3)	(19)	(9)
Avg. U.S. \$ Prices	(3)	(17)	(9)
Plastics and Chemicals			
Avg. Ps. Prices	(4)	(23)	(16)
Avg. U.S. \$ Prices	(3)	(21)	(16)
Total			
Avg. Ps. Prices	(3)	(22)	(11)
Avg. U.S. \$ Prices	(2)	(20)	(11)

TABLE 3 | INCOME STATEMENT (U.S. \$ Millions)

	4Q19	3Q19	4Q18	(% 4Q19 vs.)		2019	2018	Ch.%
				3Q19	4Q18			
Total Revenues	1,407	1,523	1,758	(8)	(20)	6,216	6,991	(11)
Gross Profit	168	213	181	(21)	(7)	675	938	(28)
Operating expenses and others	134	(74)	327	281	(59)	(34)	148	(123)
Operating income	302	139	508	117	(41)	641	1,086	(41)
Financial cost, net	(36)	(59)	(45)	39	19	(136)	(141)	3
Share of losses of associates	(16)	-	(1)	(100)	(1,263)	(16)	(2)	(965)
Income Tax	(33)	(16)	(60)	(100)	46	(98)	(178)	45
Consolidated net income	218	63	402	245	(46)	390	765	(49)
Controlling Interest	209	50	393	316	(47)	342	697	(51)

TABLE 4 | REVENUES

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
Total Revenues								
Ps. Millions	27,133	29,560	34,802	(8)	(22)	119,685	134,523	(11)
U.S. \$ Millions	1,407	1,523	1,758	(8)	(20)	6,216	6,991	(11)
Domestic Revenues								
Ps. Millions	7,837	8,943	10,195	(12)	(23)	34,592	40,289	(14)
U.S. \$ Millions	406	461	516	(12)	(21)	1,796	2,095	(14)
Foreign Revenues								
Ps. Millions	19,296	20,617	24,607	(6)	(22)	85,094	94,234	(10)
U.S. \$ Millions	1,001	1,062	1,243	(6)	(19)	4,420	4,895	(10)
Foreign / Total (%)	71	70	71			71	70	

TABLE 5 | OPERATING INCOME AND EBITDA

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
Operating Income								
Ps. Millions	5,834	2,706	10,167	116	(43)	12,361	21,202	(42)
U.S. \$ Millions	302	139	508	117	(41)	641	1,086	(41)
EBITDA								
Ps. Millions	6,863	3,771	7,355	82	(7)	16,395	20,607	(20)
U.S. \$ Millions	356	194	369	83	(4)	850	1,063	(20)

TABLE 6 | COMPARABLE EBITDA

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
EBITDA								
Ps. Millions	6,863	3,771	7,355	82	(7)	16,395	20,607	(20)
U.S. \$ Millions	356	194	369	83	(4)	850	1,063	(20)
Adjustments*								
Ps. Millions	(3,546)	367	(3,938)	(1,065)	10	(2,484)	(5,310)	53
U.S. \$ Millions	(184)	19	(188)	(1,066)	2	(128)	(259)	51
Comparable EBITDA								
Ps. Millions	3,317	4,139	3,417	(20)	(3)	13,911	15,297	(9)
U.S. \$ Millions	172	213	181	(19)	(5)	722	804	(10)

*Adjustments: Inventory and non-operating, one-time (gains) losses

TABLE 7 | FINANCIAL COST, NET (U.S. \$ Millions)

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch.%
				3Q19	4Q18			
Financial Expenses	(42)	(39)	(29)	(8)	(48)	(146)	(113)	(29)
Financial Income	16	10	8	61	105	40	23	76
Net Financial Expenses	(26)	(29)	(21)	10	(26)	(106)	(90)	(17)
Fx Gains (Losses)	(10)	(30)	(24)	68	59	(30)	(50)	40
Financial Cost, Net	(36)	(59)	(45)	39	19	(136)	(141)	3

TABLE 8 | NET INCOME (U.S. \$ Millions)

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch.%
				3Q19	4Q18			
Consolidated Net Income	218	63	402	245	(46)	390	765	(49)
Non-Controlling Interest	8	13	10	(35)	(14)	48	68	(30)
Controlling Interest	209	50	393	316	(47)	342	697	(51)
Earnings per Share (U.S. Dollars)	0.10	0.02	0.19	316	(47)	0.16	0.33	(51)
Avg. Outstanding Shares (Millions)*	2,116	2,117	2,118			2,117	2,118	

* The same number of equivalent shares are considered in the periods presented

TABLE 9 | CASH FLOW (U.S. \$ Millions)

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch.%
				3Q19	4Q18			
EBITDA	356	194	369	83	(4)	850	1,063	(20)
Net Working Capital & Others	(67)	(2)	(45)	(3,711)	(48)	(2)	(321)	99
Capital Expenditures & Acq.	(115)	(49)	(262)	(133)	56	(270)	(826)	67
Financial Expenses	(39)	(34)	(28)	(13)	(38)	(136)	(107)	(28)
Income tax	(29)	(25)	(17)	(16)	(75)	(144)	(92)	(57)
Dividends	(25)	-	(24)	(100)	(4)	(206)	(53)	(292)
Payment to affiliated companies	-	2	-	(100)	(27)	10	10	(7)
Other Sources / Uses	625	(37)	(221)	1,774	382	400	(245)	263
Decrease (Increase) in Net Debt	706	48	(228)	1,365	409	502	(569)	188

TABLE 10 | STATEMENT OF FINANCIAL POSITION & FINANCIAL RATIOS (U.S. \$ Millions)

	4Q19	3Q19	4Q18	(%) 4Q19 vs.	
				3Q19	4Q18
Assets					
Cash and cash equivalents	386	309	212	25	82
Trade accounts receivable	545	597	792	(9)	(31)
Inventories	953	914	1,245	4	(23)
Other current assets	428	407	348	5	23
Total current assets	2,312	2,226	2,597	4	(11)
Investment in associates and others	438	454	447	(4)	(2)
Property, plant and equipment, net	1,968	2,410	2,390	(18)	(18)
Goodwill and intangible assets, net	201	211	222	(5)	(10)
Other non-current assets	536	601	436	(11)	23
Total assets	5,455	5,903	6,091	(8)	(10)
Liabilities & stockholders' equity					
Debt	38	115	514	(67)	(93)
Suppliers	693	713	1,134	(3)	(39)
Other current liabilities	348	412	311	(16)	12
Total current liabilities	1,078	1,239	1,960	(13)	(45)
Debt (include debt issuance cost)	1,491	2,041	1,525	(27)	(2)
Employees' benefits	58	58	56	-	4
Other long-term liabilities	436	438	358	(1)	22
Total liabilities	3,064	3,777	3,898	(19)	(21)
Total stockholders' equity	2,391	2,125	2,193	13	9
Total liabilities & stockholders' equity	5,455	5,903	6,091	(8)	(10)
Net Debt	1,330	2,036	1,832	(35)	(27)
Net Debt/EBITDA*	1.6	2.4	1.7		
Interest Coverage*	7.2	7.8	9.9		

* Times: last 12 months

Polyester

TABLE 11 | REVENUES

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
Total Revenues								
Ps. Millions	20,731	22,553	25,623	(8)	(19)	90,857	99,559	(9)
U.S. \$ Millions	1,075	1,162	1,295	(7)	(17)	4,718	5,174	(9)
Domestic Revenues								
Ps. Millions	3,895	4,561	4,973	(15)	(22)	16,475	19,510	(16)
U.S. \$ Millions	202	235	252	(14)	(20)	855	1,015	(16)
Foreign Revenues								
Ps. Millions	16,836	17,992	20,650	(6)	(18)	74,382	80,049	(7)
U.S. \$ Millions	873	927	1,043	(6)	(16)	3,863	4,159	(7)
Foreign / Total (%)	81	80	81			82	80	

TABLE 12 | OPERATING INCOME AND EBITDA

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
Operating Income								
Ps. Millions	1,526	1,675	9,248	(9)	(84)	5,029	16,470	(69)
U.S. \$ Millions	79	86	461	(8)	(83)	261	839	(69)
EBITDA								
Ps. Millions	2,349	2,516	6,300	(7)	(63)	8,236	15,318	(46)
U.S. \$ Millions	122	129	316	(6)	(61)	428	788	(46)

TABLE 13 | COMPARABLE EBITDA

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
EBITDA								
Ps. Millions	2,349	2,516	6,300	(7)	(63)	8,236	15,318	(46)
U.S. \$ Millions	122	129	316	(6)	(61)	428	788	(46)
Adjustments*								
Ps. Millions	18	287	(4,048)	(94)	100	901	(5,289)	117
U.S. \$ Millions	1	15	(193)	(94)	100	47	(258)	118
Comparable EBITDA								
Ps. Millions	2,368	2,803	2,252	(16)	5	9,137	10,029	(9)
U.S. \$ Millions	123	144	122	(15)	-	474	529	(10)

*Adjustments: Inventory and non-operating, one-time (gains) losses

Plastics & Chemicals

TABLE 14 | REVENUES

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
Total Revenues								
Ps. Millions	6,006	6,693	7,910	(10)	(24)	27,097	32,925	(18)
U.S. \$ Millions	311	345	400	(10)	(22)	1,407	1,713	(18)
Domestic Revenues								
Ps. Millions	3,568	4,202	4,831	(15)	(26)	16,637	20,307	(18)
U.S. \$ Millions	185	217	244	(15)	(24)	864	1,057	(18)
Foreign Revenues								
Ps. Millions	2,438	2,491	3,079	(2)	(21)	10,460	12,618	(17)
U.S. \$ Millions	126	128	156	(1)	(19)	543	656	(17)
Foreign / Total (%)	41	37	39			39	38	

TABLE 15 | OPERATING INCOME AND EBITDA

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
Operating Income								
Ps. Millions	611	951	881	(36)	(31)	3,368	4,735	(29)
U.S. \$ Millions	32	49	45	(35)	(29)	175	247	(29)
EBITDA								
Ps. Millions	819	1,173	1,017	(30)	(20)	4,198	5,292	(21)
U.S. \$ Millions	42	60	52	(30)	(18)	218	276	(21)

TABLE 16 | COMPARABLE EBITDA

	4Q19	3Q19	4Q18	(%) 4Q19 vs.		2019	2018	Ch. %
				3Q19	4Q18			
EBITDA								
Ps. Millions	819	1,173	1,017	(30)	(20)	4,198	5,292	(21)
U.S. \$ Millions	42	60	52	(30)	(18)	218	276	(21)
Adjustments*								
Ps. Millions	70	81	110	(14)	(36)	249	(21)	1,262
U.S. \$ Millions	4	4	5	(13)	(33)	13	(1)	1,333
Comparable EBITDA								
Ps. Millions	888	1,254	1,127	(29)	(22)	4,447	5,271	(16)
U.S. \$ Millions	46	65	57	(29)	(19)	231	275	(16)

*Adjustments: Inventory and non-operating, one-time (gains) losses

Appendix B – Financial Statements

ALPEK, S.A.B. DE C.V. and Subsidiaries

STATEMENT OF FINANCIAL POSITION

Information in Millions of Mexican Pesos

(% Dec-19 vs.

	Dec-19	Sep-19	Dec-18	Sep-19	Dec-18
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	7,059	6,069	4,168	16	69
Restricted cash	216	3	3	6,511	7,717
Trade accounts receivable	10,265	11,714	15,579	(12)	(34)
Other accounts and notes receivable	5,658	6,630	5,643	(15)	-
Inventories	17,966	17,945	24,511	-	(27)
Other current assets	2,411	1,353	1,211	78	99
Total current assets	43,575	43,714	51,115	-	(15)
Investment in associates and others	8,246	8,919	8,794	(8)	(6)
Property, plant and equipment, net	37,082	47,322	47,033	(22)	(21)
Goodwill and intangible assets	3,783	4,138	4,368	(9)	(13)
Other non-current assets	10,108	11,811	8,587	(14)	18
Total assets	102,794	115,904	119,897	(11)	(14)
LIABILITIES AND STOCKHOLDER'S EQUITY					
CURRENT LIABILITIES:					
Debt	707	2,253	10,118	(69)	(93)
Suppliers	13,064	14,001	22,330	(7)	(41)
Other current liabilities	6,550	8,082	6,128	(19)	7
Total current liabilities	20,321	24,336	38,576	(16)	(47)
NON-CURRENT LIABILITIES:					
Debt (include debt issuance cost)	28,103	40,083	30,012	(30)	(6)
Deferred income taxes	3,926	3,873	4,752	1	(17)
Other non-current liabilities	4,294	4,736	2,295	(9)	87
Employees' benefits	1,092	1,143	1,099	(4)	(1)
Total liabilities	57,736	74,171	76,734	(22)	(25)
STOCKHOLDERS' EQUITY:					
Controlling interest:					
Capital stock	6,045	6,047	6,052	-	-
Share premium	9,059	9,077	9,106	-	(1)
Contributed capital	15,104	15,124	15,158	-	-
Earned surplus	25,376	21,522	22,969	18	10
Total controlling interest	40,480	36,646	38,127	10	6
Non-controlling interest	4,578	5,087	5,036	(10)	(9)
Total stockholders' equity	45,058	41,733	43,163	8	4
Total liabilities and stockholders' equity	102,794	115,904	119,897	(11)	(14)

ALPEK, S.A.B. DE C.V. and Subsidiaries

STATEMENT OF INCOME

Information in Millions of Mexican Pesos

	4Q19	3Q19	4Q18	(% 4Q19 vs		2019	2018	(% 2019 vs 2018
				3Q19	4Q18			
Revenues	27,133	29,560	34,802	(8)	(22)	119,685	134,523	(11)
Domestic	7,837	8,943	10,195	(12)	(23)	34,591	40,289	(14)
Export	19,296	20,617	24,607	(6)	(22)	85,094	94,234	(10)
Cost of sales	(23,883)	(25,417)	(31,245)	6	24	(106,669)	(116,519)	8
Gross profit	3,250	4,143	3,557	(22)	(9)	13,016	18,004	(28)
Operating expenses and others	2,584	(1,437)	6,610	280	(61)	(655)	3,198	(120)
Operating income	5,834	2,706	10,167	116	(43)	12,361	21,202	(42)
Financial result, net	(693)	(1,157)	(935)	40	26	(2,635)	(2,783)	5
Equity in income of associates and joint ventures	(303)	(7)	(23)	(4,223)	(1,196)	(313)	(30)	(924)
Income before taxes	4,838	1,542	9,209	214	(47)	9,413	18,389	(49)
Income taxes	(628)	(316)	(1,200)	(99)	48	(1,889)	(3,455)	45
Consolidated net income	4,210	1,226	8,009	243	(47)	7,524	14,934	(50)
Profit attributable to Controlling interest	4,047	976	7,815	315	(48)	6,605	13,633	(52)
Profit attributable to Non-controlling interest	163	250	194	(35)	(16)	919	1,301	(29)